Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NSE India Stock Exchange  >  Pfizer Limited    PFIZER   INE182A01018

PFIZER LIMITED

(PFIZER)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Amgen close to buying Onyx for $125 per share: sources

share with twitter share with LinkedIn share with facebook
share via e-mail
08/24/2013 | 05:34pm EDT

(Reuters) - Amgen Inc (>> Amgen, Inc.) is close to buying Onyx Pharmaceuticals Inc (>> Onyx Pharmaceuticals, Inc.) for $125 per share, or more than $10 billion, in a deal that is expected to be announced as soon as Monday, two people familiar with the matter said on Saturday.

(Reuters) - Amgen Inc (>> Amgen, Inc.) is close to buying Onyx Pharmaceuticals Inc (>> Onyx Pharmaceuticals, Inc.) for $125 per share, or more than $10 billion, in a deal that is expected to be announced as soon as Monday, two people familiar with the matter said on Saturday.

A deal, which is still being finalized and would require board approval from both companies, would represent the fifth-largest biotechnology deal in history.

The proposed takeover would value Onyx at 13 times the company's expected revenues for next year, one of the richest valuations in biotech takeovers, one of the people said.

The people asked not to be identified because the matter is not public. Representatives for Amgen and Onyx could not be immediately reached for comment.

The acquisition of Onyx would give Amgen full rights to Kyprolis, the new multiple myeloma drug that analysts expect to reach annual peak sales in excess of $2 billion.

Amgen would also gain a revenue stream from the liver and kidney cancer drug Nexavar that Onyx shares with Bayer AG, as well as royalty payments on Bayer's much newer colon cancer drug Stivarga and potential future royalties on an experimental breast cancer drug being developed by Pfizer.

A deal in the $10 billion range would be Amgen's biggest since its $16 billion acquisition of Immunex in 2001 that gave it the rheumatoid arthritis drug, Enbrel, which is one of Amgen's most important, biggest-selling products.

It would be by far the biggest deal under CEO Bob Bradway, who took over the top spot in May 2012. He has done a handful of much smaller deals, the biggest to date being a $1.16 billion acquisition of Micromet.

FOCUS ON ONCOLOGY

Onyx shares closed at $116.96 on Friday. Amgen offered to pay $120 per share for the company in June but Onyx said that bid significantly undervalued the company and put itself up for sale.

An Onyx deal would also give Amgen a much higher profile in oncology. Several of its current drugs offer supportive care for cancer patients, such as to treat anemia or decreases in white blood cells caused by chemotherapy.

Another of its newer medicines, Xgeva, helps prevent fractures in patients whose cancers have spread to the bone. Its one product that treats cancer, the colon cancer drug Vectibix, has largely been a disappointment.

Analysts are expecting Onyx revenue to reach $878 million in 2014, according to Thomson Reuters I/B/E/S.

Geoffrey Porges, long-time biotech analyst for Sanford Bernstein, projected that an Onyx acquisition would boost Amgen revenue by 5 percent to 6 percent near term, rising to 20 percent by 2021.

He sees Amgen EPS declining by 3 percent to 4 percent in 2014 with the purchase of Onyx, but increasing by 8 percent in 2016 and growing to an increase of 22 percent in 2019.

Two of Amgen's biggest products - the anemia drugs Aranesp and Epogen - have been in decline for years, while others are fairly mature at this point.

The New York Times first reported on Saturday that the two companies were near a deal.

(Reporting by Soyoung Kim in New York; Editing by Gunna Dickson and Xavier Briand)

By Soyoung Kim

Stocks mentioned in the article
ChangeLast1st jan.
AMGEN INC. 5.15% 208.48 Delayed Quote.-13.52%
PFIZER LIMITED 1.68% 3867.95 End-of-day quote.-9.96%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PFIZER LIMITED
03/04Europe 'panicking' over India's pharmaceutical export curbs - industry group
RE
2019Longtime Abbott Labs CEO Miles White to Step Down in March -- Update
DJ
2019PFIZER, MERCK KGAA : Bavencio Misses Main Endpoint in Gastric Cancer Study
DJ
2019Google Counts on Fitbit to Make Imprint in Health Market
DJ
2019Amgen To Invest In Chinese Biotech -- WSJ
DJ
2019Amgen to Buy Stake in Chinese Cancer-Drugmaker BeiGene -- Update
DJ
2019Bristol-Myers posts better-than-expected results, Opdivo growth slows
RE
2019GlaxoSmithKline Raises Guidance After 3Q Profit Rise -- Update
DJ
2019New Products Help Pfizer Boost Outlook -- WSJ
DJ
2019S&P 500 pulls back from record high
RE
More news
Financials (INR)
Sales 2020 22 449 M
EBIT 2020 5 558 M
Net income 2020 5 323 M
Debt 2020 -
Yield 2020 0,64%
P/E ratio 2020 32,8x
P/E ratio 2021 30,3x
Capi. / Sales2020 7,89x
Capi. / Sales2021 7,40x
Capitalization 177 B
Chart PFIZER LIMITED
Duration : Period :
Pfizer Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 3 869,60  
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Sridhar Subramaniam Managing Director & Executive Director
Rajendra Ambalal Shah Chairman
Deepak Rakheja Director-Global Commercial Operations
Milind Patil Chief Financial Officer & Executive Director
Navin Singhania Director-Business Technology
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER LIMITED-9.96%2 316
JOHNSON & JOHNSON-15.57%324 693
ROCHE HOLDING AG-5.53%264 026
MERCK & CO., INC-15.39%181 927
NOVARTIS-17.30%180 007
PFIZER, INC.-16.62%171 422